857904-11-1

Basic information

• Product Name: HYDRAZINECARBOXYLIC ACID, [[4-(2-PYRIDINYL)PHENYL]METHYLENE]-, 1,1-DIMETHYLETHYL ESTER
• Synonyms: Hydrazinecarboxylic acid, 2-[[4-(2-pyridinyl)phenyl]methylene]-, 1,1-dimethylethyl ester, (2E)-
• CAS NO: 857904-11-1
• Molecular Formula: C₁₇H₁₉N₃O₂
• Molecular Weight: 297.35
• Mol File: 857904-11-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: HYDRAZINECARBOXYLIC ACID, [[4-(2-PYRIDINYL)PHENYL]METHYLENE]-, 1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: HYDRAZINECARBOXYLIC ACID, [[4-(2-PYRIDINYL)PHENYL]METHYLENE]-, 1,1-DIMETHYLETHYL ESTER(857904-11-1)
• EPA Substance Registry System: HYDRAZINECARBOXYLIC ACID, [[4-(2-PYRIDINYL)PHENYL]METHYLENE]-, 1,1-DIMETHYLETHYL ESTER(857904-11-1)

Safety Data

• Hazardous Substances Data: 857904-11-1(Hazardous Substances Data)

Upstream product

• 24856-58-4 1,1-dimethoxy-1-(4-bromophenyl)methane 
• 109-04-6 2-bromo-pyridine 
• 127406-56-8 4-(2'-pyridyl)benzaldehyde 
• 870-46-2 t-butoxycarbonylhydrazine 

Downstream Products

• 198904-86-8 1-[4-(pyridine-2-yl)phenyl]-5(S)-2,5-bis[(tert-butyloxycarbonyl)amino]-4(S)-hydroxy-6-phenyl-2-azahexane 
• 198904-31-3 atazanavir 
• 198904-22-2 1-[4-(Pyridin-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-bis[N-(N-methoxycarbonyl-(L)-valyl)amino]-6-phenyl-2-azahexane 
• 198905-13-4 N'-[(2S,3S)-2-Hydroxy-3-((2S,3S)-2-methoxycarbonylamino-3-methyl-pentanoylamino)-4-phenyl-butyl]-N'-(4-pyridin-2-yl-benzyl)-hydrazinecarboxylic acid tert-butyl ester 
• 198905-15-6 N'-[(2S,3S)-2-Hydroxy-3-((S)-2-methoxycarbonylamino-3-methyl-butyrylamino)-4-phenyl-butyl]-N'-(4-pyridin-2-yl-benzyl)-hydrazinecarboxylic acid tert-butyl ester 
• 198905-04-3 1-[4-(pyridine-2-yl)-phenyl]-4(S)-hydroxy-2-N-tert-butoxycarbonylamino-5(S)-N-(N-methoxycarbonyl-(L)-tert-leucyl)amino-6-phenyl-2-azahexane 
• 198905-11-2 1-[4-(Pyridin-2-yl)-phenyl]-4(S)-hydroxy-2-(N-Boc-amino)-5(S)-trifluoroacetyl-amino-6-phenyl-2-azahexane 
• 198904-87-9 1-[4-(pyridin-2-yl)phenyl]-4(S)-hydroxy-5(S)-2,5-diamino-6-phenyl-2-azahexane trihydrochloride 
• 198905-12-3 tert-butyl 2-((2S,3S)-2-hydroxy-4-phenyl-3-(amino)butyl)-2-(4-pyridin-2-ylbenzyl)hydrazinecarboxylate 
• 198904-85-7 N-1-(tert-butoxycarbonyl)-N-2-[4-(pyridine-2-yl)benzyl]hydrazine 

Relevant articles and documents

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: Candidates for clinical development

On the basis of previously described X-ray studies of an enzyme/aza- dipeptide complex, aza-dipeptide analogues carrying N-(bis-aryl-methyl) substituents on the (hydroxethyl)hydrazine moiety have been designed and synthesized as HIV-1 protease inhibitors. By using either equally (12) or orthogonally (13) protected dipeptide isosteres, symmetrically and asymmetrically acylated aza-dipeptides can be synthesized. This approach led to the discovery of very potent inhibitors with antiviral activities (ED50) in the subnanomolar range. Acylation of the (hydroxethyl)hydrazine dipeptide isostere with the L-tert-leucine derivative 29 increased the oral bioavailability significantly when compared to the corresponding L-valine or L-isoleucine derivatives. The bis (L-tert-leucine) derivatives CGP 75355, CGP 73547, CGP 75136, and CGP 75176 combine excellent antiviral activity with high blood concentration after oral administration. Furthermore, they show no cross-resistance with saquinavir-resistant strains and maintain activity against indinavir-resistant ones. Consequently they qualify for further profiling as potential clinical candidates.